Results 161 to 170 of about 12,522 (293)

Exploring Exercise as Airway Clearance in Cystic Fibrosis: A Qualitative Study From the ExACT‐CF Feasibility Trial

Pediatric Pulmonology, Volume 61, Issue 1, January 2026.
ABSTRACT Question Cystic fibrosis (CF) affects > 11,300 people in the UK and is characterized by thick, sticky mucus in the lungs, leading to recurrent infections, inflammation, and progressive respiratory decline. Chest physiotherapy remains a cornerstone of airway clearance; however, many people with CF (pwCF) find it burdensome and time‐consuming ...
Emily Taylor, Dia Soilemezi, Don S. Urquhart, Steve Cunningham, Steff Lewis, Aileen Rae Neilson, Hannah Ensor, Ioannis Vogiatizis, Lorna Allen, Zoe L. Saynor, the ExACT‐CF study group, Don S. Urquhart, Emily Taylor, Steve Cunningham, Steff Lewis, Aileen Rae Neilson, Dia Soilemezi, Hannah Ensor, Ioannis Vogiatizis, Lorna Allen, Debbie Miller, Donna Bowen, Ellyse Kilarski, Ellen Lacey, Gary Connett, Julian Legg, Hazel Evans, Thomas Daniels, Mark Allenby, Mary Carroll, Robert Gray, Carlos Echevarria, Lisa Morrison, Gordon McGregor, Mary Abkir, Clare Saunders, Zoe L. Saynor   +36 more
wiley   +1 more source

Pharmacokinetics of Ivacaftor, Tezacaftor, Elexacaftor, and Lumacaftor in Special Cystic Fibrosis Populations:A Systematic Review [PDF]

BACKGROUND AND OBJECTIVE: Following the development of cystic fibrosis transmembrane conductance regulator (CFTR) modulators (ivacaftor, tezacaftor, elexacaftor, and lumacaftor), the prognosis for people diagnosed with cystic fibrosis (pwCF) has improved.
Akkerman, Onno W, Elzinga, Femke A, Koppelman, Gerard H, Malik, Paul R V, Mian, Paola, Rottier, Bart L, Touw, Daan J, van der Vaart, Hester   +7 more
core   +1 more source

311 Active Pseudomonas aeruginosa infection of primary airway epithelia enhances CFTR modulator rescue [PDF]

, 2023
Deborah M. Cholon, M. Higgs, Susan E. Boyles, Nancy L. Quinney, S. Meinig, John T. Minges, Carla M. P. Ribeiro, Matthew C. Wolfgang, Martina Gentzsch   +8 more
openalex   +1 more source

A Case of Cystic Fibrosis in a Japanese Man With Congenital Bilateral Absence of the Vas Deferens and Recurrent Pancreatitis Caused by a Homozygous c.1210‐11 T > G Variant of the Cystic Fibrosis Transmembrane Conductance Regulator Gene

Reproductive Medicine and Biology, Volume 25, Issue 1, January/December 2026.
ABSTRACT Case We herein report a rare case of a Japanese man diagnosed with cystic fibrosis (CF) following a workup for male infertility and recurrent pancreatitis and discuss the clinical and diagnostic implications in a population wherein CF is exceptionally rare. A 27‐year‐old Japanese man who presented with azoospermia underwent clinical evaluation,
Tomoki Saito, Shinnosuke Kuroda, Teppei Takeshima, Takashi Kawahara, Junichi Teranishi, Jurii Karibe, Fuka Anzai, Miki Tanoshima, Kazuhide Makiyama, Yasushi Yumura   +9 more
wiley   +1 more source

Lipid Nanoparticles for Delivery of CRISPR Gene Editing Components

Small Methods, Volume 10, Issue 2, 22 January 2026.
The review presents a comprehensive overview of each component of lipid nanoparticles（LNPs）and their effects on editing efficiency. It specifically highlights strategies for achieving non‐liver delivery, aiming for broader applications in gene editing. Furthermore, this review summarizes the applications of LNPs in gene editing and offers insights for ...
Fan Wu, Nei Li, Yudian Xiao, Rohan Palanki, Hannah Yamagata, Michael J. Mitchell, Xuexiang Han   +6 more
wiley   +1 more source

In utero and postnatal ivacaftor/lumacaftor therapy rescues multiorgan disease in CFTR-F508del ferrets

JCI Insight
Cystic fibrosis (CF) is caused by mutations in the CF transmembrane conductance regulator (CFTR) gene, with F508del being the most prevalent mutation.
Idil Apak Evans, Xingshen Sun, Bo Liang, Amber R. Vegter, Lydia Guo, Thomas J. Lynch, Yan Zhang, Yulong Zhang, Yaling Yi, Yu Yang, Zehua Feng, Soo Yeun Park, Amanita Shonka, Hannah McCumber, Lisi Qi, Peipei Wu, Guangming Liu, Allison Lacina, Kai Wang, Katherine N. Gibson-Corley, David K. Meyerholz, Dominique H. Limoli, Bradley H. Rosen, Ziying Yan, Douglas J. Bartels, John F. Engelhardt   +25 more
doaj   +1 more source

β‐Hydroxybutyrate Acts as an Exercise Mimetic to Protect the Aging Liver

Aging Cell, Volume 25, Issue 1, January 2026.
β‐hydroxybutyrate (β‐HB) acts as an exercise mimetic to protect the aging liver. In aged models, exercise‐induced β‐HB delays liver aging by reversing macrophage senescence, blocking mtDNA/cGAS‐STING‐driven inflammation, and alleviating hepatocyte lipid deposition/PANoptosis.
Ke Li, Lian Wang, Danlin Zhu, Wenhong Wang, Yifan Guo, Haoyang Gao, Muge Zhou, Weihua Xiao   +7 more
wiley   +1 more source

UK Biobank: Transforming drug discovery and precision medicine

British Journal of Pharmacology, Volume 183, Issue 2, Page 234-248, January 2026.
UK Biobank is a large‐scale, prospective study with extensive genetic and phenotypic data on half a million individuals. Volunteers, aged between 40 and 69 years, were recruited between 2006 and 2010 from the general population of the United Kingdom.
Jelena Bešević, Saredo Said, Reka Nagy, Yalda Jamshidi, Christopher D. Whelan, Lauren Carson, Martin K. Rutter, Adam J. Lewandowski, Mark Effingham, Rory Collins, Ben Lacey, Naomi E. Allen   +11 more
wiley   +1 more source

Novel CFTR Modulators for Treating Cystic Fibrosis [PDF]

ACS Medicinal Chemistry Letters, 2021
openaire   +3 more sources

Profile of tezacaftor/ivacaftor combination and its potential in the treatment of cystic fibrosis

Therapeutics and Clinical Risk Management, 2019
Dejene Shiferaw,* Shoaib Faruqi*Department of Respiratory Medicine, Hull University Teaching Hospitals NHS Trust, Cottingham HU16 5JQ, UK *These authors contributed equally to this workCorrespondence: Shoaib FaruqiDepartment of Respiratory Medicine ...
Shiferaw D, Faruqi S
doaj